(Q36223272)

12 August 2017

1 reference

title

Pharmacology of vigabatrin (English)

1 reference

12 August 2017

Pharmacology of Vigabatrin (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

14 October 2022

1 reference

1

A. Sabers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1608908

14 October 2022

author name string

L. Gram

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1608908

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1608908

14 October 2022

publication date

1 April 1992

1 reference

full work available at URL

12 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0773.1992.tb00465.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0773.1992.tb00465.x/fullpdf

14 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Basic and Clinical Pharmacology and Toxicology

14 October 2022

published in

1 reference

12 August 2017

volume

70

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

237-243

1 reference

Effects of vigabatrin on evoked potentials in dogs

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Effect of food on the absorption of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Neuropathology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Vigabatrin in the treatment of epilepsy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Response to vigabatrin in relation to seizure type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Interaction between vigabatrin and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Clinical pharmacology of vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0773.1992.TB00465.X

Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans

14 October 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy

14 October 2022

4

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up

14 October 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats

14 October 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

The neuropathology of vigabatrin

14 October 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

The relationship between GABA concentrations in brain and cerebrospinal fluid

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin in infantile spasms

14 October 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin in complex partial seizures: a long-term study

14 October 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy

14 October 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

14 October 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy

14 October 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy

14 October 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons

14 October 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

14 October 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid)

14 October 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Assay of gamma-vinyl-gamma-aminobutyric acid (4-amino-hex-5-enoic acid) in plasma and urine by automatic amino acid analysis. Application to human pharmacokinetics

14 October 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer

14 October 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Pharmacokinetics of vigabatrin: implications of creatinine clearance

14 October 2022

22

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin

14 October 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice

14 October 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes

14 October 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients

14 October 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine.

14 October 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy.

14 October 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study

14 October 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Effect of microinjections of gamma-vinyl GABA or isoniazid into substantia nigra on the development of amygdala kindling in rats

14 October 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Epilepsy and γ-Aminobutyric Acid-Mediated Inhibition

14 October 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, ?-acetylenic GABA (4-amino-hex-5-ynoic acid) and ?-vinyl GABA (4-amino-hex-5-enoic acid)

14 October 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Anticonvulsant action in mice with sound-induced seizures of the optical isomers of gamma-vinyl GABA

14 October 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Electrophysiologic effects of gamma-vinyl GABA and carbamazepine

14 October 2022

36

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

The pharmacology of GABA-transaminase inhibitors

14 October 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin: no microvacuoles in a human brain.

14 October 2022

41

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain

14 October 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Specificity of vigabatrin for the GABAergic system in human epilepsy

14 October 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy

14 October 2022

46

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin: rational treatment for chronic epilepsy

14 October 2022

49

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy

14 October 2022

51

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

14 October 2022

Vigabatrin and psychosis

52

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Metabolic inhibitors and subcellular distribution of GABA

14 October 2022

53

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors

14 October 2022

54

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice

14 October 2022

55

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Attempts to Correlate Alterations in Brain GABA Metabolism by GABA-T Inhibitors with Their Anticonvulsant Effects

14 October 2022

57

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy

14 October 2022

58

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes.

14 October 2022

61

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Anti-seizure and anti-epileptogenic effect of gamma-vinyl gamma-aminobutyric acid in amygdaloid kindling.

14 October 2022

62

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Double-blind dose reduction study of vigabatrin in complex partial epilepsy.

14 October 2022

63

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.

14 October 2022

64

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Vigabatrin in the treatment of epilepsy: a long-term follow-up study

14 October 2022

65

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy

14 October 2022

66

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

The role of gamma-aminobutyric acid in the mechanism of seizures

14 October 2022

69

1 reference

https://api.crossref.org/works/10.1111/J.1600-0773.1992.TB00465.X

14 October 2022

Identifiers

1 reference

12 August 2017

1 reference